Abstract
Heart failure is a highly prevalent health problem in our population with significant economic impact considering both direct and indirect costs. There are few studies that have assessed the overall cost of heart failure.
In the study published in this journal, an evaluation of costs is conducted, with hospitalization being the main expense. Therefore, strategies aimed at reducing hospitalization as a means of cost reduction are of great interest, highlighting the role of sodium-glucose transporter inhibitors (SGLT2 inhibitors), the management of comorbidities, enhancing measures aimed at education and self-care with a crucial role of palliative care and specific heart failure programs.
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Copyright (c) 2024 GaliciaClinica - Official Journal of the Galician Society of Internal Medicine (SOGAMI)